178 related articles for article (PubMed ID: 31578141)
1. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
[TBL] [Abstract][Full Text] [Related]
2. External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.
Erdem S; Capitanio U; Campi R; Mir MC; Roussel E; Pavan N; Kara O; Klatte T; Kriegmair MC; Degirmenci E; Aydin R; Minervini A; Serni S; Berni A; Rebez G; Ozcan F;
Urol Oncol; 2022 May; 40(5):198.e9-198.e17. PubMed ID: 35172939
[TBL] [Abstract][Full Text] [Related]
3. Comparison and validation of different risk models for papillary renal cell carcinoma.
Lin H; Sun Q; Li Z; Zheng J; Zhang X; Xiong Y; Chen H; Hou Y; Xi W; Lin J
Urol Oncol; 2023 Aug; 41(8):358.e1-358.e7. PubMed ID: 37394414
[TBL] [Abstract][Full Text] [Related]
4. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
Correa AF; Jegede O; Haas NB; Flaherty KT; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
J Clin Oncol; 2019 Aug; 37(23):2062-2071. PubMed ID: 31216227
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.
Rosenkrantz AB; Sekhar A; Genega EM; Melamed J; Babb JS; Patel AD; Lo A; Najarian RM; Ahmed M; Pedrosa I
Eur Radiol; 2013 Feb; 23(2):579-87. PubMed ID: 22903703
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
[TBL] [Abstract][Full Text] [Related]
8. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.
Abel EJ; Masterson TA; Karam JA; Master VA; Margulis V; Hutchinson R; Lorentz CA; Bloom E; Bauman TM; Wood CG; Blute ML
J Urol; 2017 Oct; 198(4):810-816. PubMed ID: 28411071
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
10. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.
Zucchi A; Novara G; Costantini E; Antonelli A; Carini M; Carmignani G; Cosciani Cunico S; Fontana D; Longo N; Martignoni G; Minervini A; Mirone V; Porena M; Roscigno M; Schiavina R; Simeone C; Simonato A; Siracusano S; Terrone C; Ficarra V
BJU Int; 2012 Apr; 109(8):1140-6. PubMed ID: 21871053
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
[TBL] [Abstract][Full Text] [Related]
13. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
[TBL] [Abstract][Full Text] [Related]
14. Is imagery distinctive in papillary renal cell carcinoma subtypes?
Karray O; Ayed H; Saadi A; Zaghbib S; Henchir S; Cherif A; Ben Miled A; Chakroun M; Bouzouita A; Derouiche A; Ben Slama R; Chebil M
Tunis Med; 2020 Feb; 98(2):131-137. PubMed ID: 32395802
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes.
Haddad MM; Schmit GD; Kurup AN; Schmitz JJ; Boorjian SA; Geske J; Thompson RH; Callstrom MR; Atwell TD
J Vasc Interv Radiol; 2018 Aug; 29(8):1122-1126. PubMed ID: 29887184
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
[TBL] [Abstract][Full Text] [Related]
17. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy.
Cindolo L; Chiodini P; Gallo C; Ficarra V; Schips L; Tostain J; de La Taille A; Artibani W; Patard JJ
Cancer; 2008 Jul; 113(1):65-71. PubMed ID: 18473356
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
19. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Buti S; Puligandla M; Bersanelli M; DiPaola RS; Manola J; Taguchi S; Haas NB
Ann Oncol; 2017 Nov; 28(11):2747-2753. PubMed ID: 28945839
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma.
Huang J; Dahl DM; Dong L; Liu Q; Cornejo K; Wang Q; Wu S; Feldman AS; Huang Y; Xue W; Wu CL
Biomed Res Int; 2015; 2015():891045. PubMed ID: 26448948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
